Synopsis
Synopsis
0
VMF
Annual Reports
NA
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 2-(imidazol-1-yl)-1-hydroxyethylidene-1,1-bisphosphonic Acid
2. Cgp 42'446
3. Cgp 42446
4. Cgp 42446a
5. Cgp-42'446
6. Cgp-42446
7. Cgp42'446
8. Cgp42446
9. Zoledronate
10. Zoledronic Acid Anhydrous
11. Zometa
1. Zoledronate
2. 118072-93-8
3. Zometa
4. Reclast
5. Aclasta
6. (1-hydroxy-2-(1h-imidazol-1-yl)ethane-1,1-diyl)diphosphonic Acid
7. Cgp 42446
8. (1-hydroxy-2-imidazol-1-ylethylidene)diphosphonic Acid
9. Zoledronic Acid Anhydrous
10. Anhydrous Zoledronic Acid
11. (1-hydroxy-2-imidazol-1-yl-1-phosphonoethyl)phosphonic Acid
12. Phosphonic Acid, [1-hydroxy-2-(1h-imidazol-1-yl)ethylidene]bis-
13. Zol
14. [1-hydroxy-2-(1h-imidazol-1-yl)ethane-1,1-diyl]bis(phosphonic Acid)
15. Orazol
16. Zol 446
17. Zoledronic Acid (inn)
18. Cgp-42446
19. Reclast (tn)
20. Zometa (tn)
21. Chembl924
22. Zoledronic Acid Teva
23. Zoledronic Acid, Anhydrous
24. Nsc-721517
25. Zoledronic Acid Medac
26. Chebi:46557
27. [1-hydroxy-2-(1h-imidazol-1-yl)-1-phosphonoethyl]phosphonic Acid
28. 70hz18ph24
29. Ncgc00159521-02
30. (1-hydroxy-2-(1h-imidazol-1-yl)ethylidene)bisphosphonic Acid
31. Cgp-42446a
32. Zoledronate Hydrate
33. Zoledronic Acid [usan:inn:ban]
34. Phosphonic Acid, (1-hydroxy-2-(1h-imidazol-1-yl)ethylidene)bis-
35. Zoladrona Acid Mylan
36. Zoledronic
37. Zoledronic Acid Accord
38. Zoledronic Acid [inn]
39. Zomera
40. 1-hydroxy-2-(1h-imidazol-1-yl)ethane-1,1-diyldiphosphonic Acid
41. Bisphosphonate 3
42. Zometa (novartis)
43. Aclasta And Reclast
44. C5h10n2o7p2
45. [1-hydroxy-2-(1h-imidazol-1-yl)ethylidene]bisphosphonic Acid
46. Zoledronic-acid
47. Unii-70hz18ph24
48. Bph 91
49. [1-hydroxy-2-(1h-imidazol-1-yl)-ethylidene]bisphosphonic Acid
50. Dsstox_cid_22668
51. Dsstox_rid_80065
52. Zoledronic Acid, Zoledronate
53. Bidd:pxr0134
54. Dsstox_gsid_42668
55. Schembl19054
56. Zoledronic Acid [mi]
57. Bidd:gt0292
58. Zoledronic Acid (zoledronate)
59. Gtpl3177
60. Jmc515594 Compound 55
61. Dtxsid0042668
62. Bdbm12578
63. Cgp42446a
64. Zoledronic Acid [who-dd]
65. Hms2089o09
66. Bcp22750
67. Cgp-4244
68. Zinc3803652
69. Tox21_111739
70. Mfcd00867791
71. Nsc721517
72. S1314
73. Stl452893
74. Akos005145739
75. Ab07564
76. Ac-1092
77. Cs-1829
78. Db00399
79. Hs-0091
80. Nsc 721517
81. Ncgc00159521-03
82. Ncgc00159521-04
83. Ncgc00159521-05
84. Ncgc00159521-09
85. Ncgc00159521-18
86. Hy-13777
87. Cas-118072-93-8
88. Ft-0601384
89. Z0031
90. D08689
91. H11422
92. S00092
93. Ab01273947-01
94. Ab01273947-02
95. Ab01273947-03
96. Ab01273947_04
97. 072z938
98. A803876
99. Q218507
100. Sr-05000001436
101. Q-201946
102. Sr-05000001436-1
103. 1-hydroxy-2-(1-imidazolyl)ethane-1,1-diphosphonic Acid
104. Z1691545083
105. (1-hydroxy-2-(1h-imidazol-1-yl)ethane-1,1-diyl)diphosphonicacid
Molecular Weight | 272.09 g/mol |
---|---|
Molecular Formula | C5H10N2O7P2 |
XLogP3 | -4.3 |
Hydrogen Bond Donor Count | 5 |
Hydrogen Bond Acceptor Count | 8 |
Rotatable Bond Count | 4 |
Exact Mass | 271.99632466 g/mol |
Monoisotopic Mass | 271.99632466 g/mol |
Topological Polar Surface Area | 153 Ų |
Heavy Atom Count | 16 |
Formal Charge | 0 |
Complexity | 327 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 6 | |
---|---|
Drug Name | Reclast |
Drug Label | Reclast contains zoledronic acid, a bisphosphonic acid which is an inhibitor of osteoclastic bone resorption. Zoledronic acid is designated chemically as (1-Hydroxy-2-imidazol-1-yl-phosphonoethyl) phosphonic acid monohydrate and its structural formul... |
Active Ingredient | Zoledronic acid |
Dosage Form | Injectable |
Route | injection; Iv (infusion) |
Strength | eq 5mg base/100ml; 5mg/100ml |
Market Status | Prescription |
Company | Novartis Pharms; Novartis |
2 of 6 | |
---|---|
Drug Name | Zoledronic acid |
PubMed Health | Zoledronic Acid (Injection) |
Drug Classes | Calcium Regulator |
Drug Label | Zoledronic Acid Injection contains zoledronic acid, a bisphosphonic acid which is an inhibitor of osteoclastic bone resorption. Zoledronic acid is designated chemically as (1-Hydroxy-2-imidazol-1-yl-phosphonoethyl) phosphonic acid monohydrate and its... |
Active Ingredient | Zoledronic acid |
Dosage Form | Injectable |
Route | injection; Iv (infusion); Injection; iv (infusion) |
Strength | eq 5mg base/100ml; 5mg/100ml; 4mmg; eq 4mg base/100ml; eq 4mg base/5ml; 4mg/100ml; 4mg/5ml(0.8mg/ml); eq 4mg base/vial |
Market Status | Tentative Approval; Prescription |
Company | Pharmaceutics; Hospira; Gland Pharma; Teva Parenteral; Apotex; Hikma Farmaceutica; Usv North America; Acs Dobfar Info Sa; Pharmaforce; Cipla; Sun Pharma Global; Emcure Pharms; Pharms; Dr Reddys Labs; Agila Speclts; Actavis; Akorn |
3 of 6 | |
---|---|
Drug Name | Zometa |
PubMed Health | Zoledronic Acid (Injection) |
Drug Classes | Calcium Regulator |
Drug Label | Zometa contains zoledronicacid, a bisphosphonic acid which is an inhibitor of osteoclastic bone resorption. Zoledronicacid is designated chemically as (1-Hydroxy-2-imidazol-1-yl-phosphonoethyl) phosphonic acid monohydrate and its structural formu... |
Active Ingredient | Zoledronic acid |
Dosage Form | Injectable |
Route | Iv (infusion); iv (infusion) |
Strength | eq 4mg base/100ml; eq 4mg base/5ml; eq 4mg base/vial |
Market Status | Prescription |
Company | Novartis |
4 of 6 | |
---|---|
Drug Name | Reclast |
Drug Label | Reclast contains zoledronic acid, a bisphosphonic acid which is an inhibitor of osteoclastic bone resorption. Zoledronic acid is designated chemically as (1-Hydroxy-2-imidazol-1-yl-phosphonoethyl) phosphonic acid monohydrate and its structural formul... |
Active Ingredient | Zoledronic acid |
Dosage Form | Injectable |
Route | injection; Iv (infusion) |
Strength | eq 5mg base/100ml; 5mg/100ml |
Market Status | Prescription |
Company | Novartis Pharms; Novartis |
5 of 6 | |
---|---|
Drug Name | Zoledronic acid |
PubMed Health | Zoledronic Acid (Injection) |
Drug Classes | Calcium Regulator |
Drug Label | Zoledronic Acid Injection contains zoledronic acid, a bisphosphonic acid which is an inhibitor of osteoclastic bone resorption. Zoledronic acid is designated chemically as (1-Hydroxy-2-imidazol-1-yl-phosphonoethyl) phosphonic acid monohydrate and its... |
Active Ingredient | Zoledronic acid |
Dosage Form | Injectable |
Route | injection; Iv (infusion); Injection; iv (infusion) |
Strength | eq 5mg base/100ml; 5mg/100ml; 4mmg; eq 4mg base/100ml; eq 4mg base/5ml; 4mg/100ml; 4mg/5ml(0.8mg/ml); eq 4mg base/vial |
Market Status | Tentative Approval; Prescription |
Company | Pharmaceutics; Hospira; Gland Pharma; Teva Parenteral; Apotex; Hikma Farmaceutica; Usv North America; Acs Dobfar Info Sa; Pharmaforce; Cipla; Sun Pharma Global; Emcure Pharms; Pharms; Dr Reddys Labs; Agila Speclts; Actavis; Akorn |
6 of 6 | |
---|---|
Drug Name | Zometa |
PubMed Health | Zoledronic Acid (Injection) |
Drug Classes | Calcium Regulator |
Drug Label | Zometa contains zoledronicacid, a bisphosphonic acid which is an inhibitor of osteoclastic bone resorption. Zoledronicacid is designated chemically as (1-Hydroxy-2-imidazol-1-yl-phosphonoethyl) phosphonic acid monohydrate and its structural formu... |
Active Ingredient | Zoledronic acid |
Dosage Form | Injectable |
Route | Iv (infusion); iv (infusion) |
Strength | eq 4mg base/100ml; eq 4mg base/5ml; eq 4mg base/vial |
Market Status | Prescription |
Company | Novartis |
Zoledronic acid is indicated to treat hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, osteoporosis in men and postmenopausal women, glucocorticoid induced osteoporosis, and Paget's disease of bone in men and women. Zoledronic acid is also indicated for the prevention of osteoporosis in post menopausal women and glucocorticoid induced osteoporosis.
Prevention of skeletal-related events and treatment of tumour-induced hypercalcaemia.
Prevention of skeletal-related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone.
Treatment of adult patients with tumour-induced hypercalcaemia.
* 4 mg / 5 ml and 4 mg / 100 ml: :
- Prevention of skeletal-related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone.
- Treatment of adult patients with tumour-induced hypercalcaemia (TIH).
* 5 mg / 100 ml: :
Treatment of osteoporosis:
- in post-menopausal women;
- in men;
at increased risk of fracture, including those with a recent low-trauma hip fracture.
Treatment of osteoporosis associated with long-term systemic glucocorticoid therapy:
- in post-menopausal women;
- in men;
at increased risk of fracture.
Treatment of Paget's disease of the bone in adults.
Prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone.
Treatment of adult patients with tumour-induced hypercalcaemia (TIH).
- Prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone;
- treatment of adult patients with tumour-induced hypercalcaemia (TIH).
Treatment of osteoporosis:
- in post-menopausal women;
- in men;
at increased risk of fracture, including those with a recent low-trauma hip fracture.
Treatment of osteoporosis associated with long-term systemic glucocorticoid therapy in post-menopausal women and in men at increased risk of fracture.
Treatment of Paget's disease of the bone.
Prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone.
Treatment of adult patients with tumour-induced hypercalcaemia (TIH).
Treatment of osteoporosis:
- in post-menopausal women;
- in men;
at increased risk of fracture including those with a recent low-trauma hip fracture.
Treatment of osteoporosis associated with long-term systemic glucocorticoid therapy:
- in post-menopausal women;
- in men;
at increased risk of fracture.
Treatment of Pagets disease of the bone in adults.
- Prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in patients with advanced malignancies involving bone;
- treatment of tumour-induced hypercalcaemia (TIH);
- prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in patients with advanced malignancies involving bone;
- treatment of tumour-induced hypercalcaemia (TIH);
- prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone;
- treatment of adult patients with tumour-induced hypercalcaemia (TIH).
Treatment of osteoporosis
- in post-menopausal women
- in adult men
at increased risk of fracture, including those with recent low-trauma hip fracture.
Treatment of osteoporosis associated with long-term systemic glucocorticoid therapy
- in post-menopausal women
- in adult men
at increased risk of fracture.
Treatment of Paget's disease of the bone in adults.
Osteogenesis imperfecta, Prevention of fracture and bone loss in postmenopausal women with early-stage breast cancer treated with aromatase inhibitors, Prevention of skeletal related events in patients with advanced malignancies involving bone, Tumour-induced hypercalcaemia
Treatment of osteoporosis, Treatment of Pagets disease of the bone
Zoledronic acid is a third generation, nitrogen containing bisphosphonate that inhibits osteoclast function and prevents bone resorption. The therapeutic window is wide as patients are unlikely to suffer severe effects from overdoses and the duration of action is long. Patients should be counselled regarding the risk of electrolyte deficiencies, renal impairment, osteonecrosis of the jaw, atypical femoral fractures, bronchoconstriction, hepatic impairment, hypocalcemia, and embryo-fetal toxicity.
Bone Density Conservation Agents
Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS. (See all compounds classified as Bone Density Conservation Agents.)
M05BA08
M05BA08
M05BA08
M05BA08
M05BA08
M05BA08
M05BA08
M05BA08
M05BA08
M05BA08
M05BA08
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
M - Musculo-skeletal system
M05 - Drugs for treatment of bone diseases
M05B - Drugs affecting bone structure and mineralization
M05BA - Bisphosphonates
M05BA08 - Zoledronic acid
Absorption
A 4mg intravenous dose reaches a Cmax of 37078.5ng/mL, with a Tmax of 0.3170.014h, and an AUC of 788181ng\*h/mL. A 5mg intravenous dose reaches a Cmax of 47176.1ng/mL, with a Tmax of 0.3680.005h, and an AUC of 917226ng\*h/mL.
Route of Elimination
Zoledronic acid is 39 16% eliminated in the urine as the unmetabolized parent drug.
Clearance
Zoledronic acid has a renal clearance of 3.7 2.0 L/h.
Zoledronic acid is not metabolized _in vivio_.
Zoledronic acid has a terminal elimination half life of 146 hours.
Bisphosphonates are taken into the bone where they bind to hydroxyapatite. Bone resorption by osteoclasts causes local acidification, releasing the bisphosphonate, which is taken into the osteoclast by fluid-phase endocytosis. Endocytic vesicles become acidified, releasing bisphosphonates into the cytosol of osteoclasts where they act. Osteoclasts mediate resorption of bone. When osteoclasts bind to bone they form podosomes, ring structures of F-actin. Etidronic acid also inhibits V-ATPases in the osteoclast, though the exact subunits are unknown, preventing F-actin from forming podosomes. Disruption of the podosomes causes osteoclasts to detach from bones, preventing bone resorption. Nitrogen containing bisphosphonates such as zoledronate are known to induce apoptosis of hematopoietic tumor cells by inhibiting the components of the mevalonate pathway farnesyl diphosphate synthase, farnesyl diphosphate, and geranylgeranyl diphosphate. These components are essential for post-translational prenylation of GTP-binding proteins like Rap1. The lack of prenylation of these proteins interferes with their function, and in the case of Rap1, leads to apoptosis. zoledronate also activated caspases which further contribute to apoptosis.
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
56
PharmaCompass offers a list of Zoledronic Acid API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Zoledronic Acid manufacturer or Zoledronic Acid supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Zoledronic Acid manufacturer or Zoledronic Acid supplier.
PharmaCompass also assists you with knowing the Zoledronic Acid API Price utilized in the formulation of products. Zoledronic Acid API Price is not always fixed or binding as the Zoledronic Acid Price is obtained through a variety of data sources. The Zoledronic Acid Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Reclast manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Reclast, including repackagers and relabelers. The FDA regulates Reclast manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Reclast API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Reclast manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Reclast supplier is an individual or a company that provides Reclast active pharmaceutical ingredient (API) or Reclast finished formulations upon request. The Reclast suppliers may include Reclast API manufacturers, exporters, distributors and traders.
click here to find a list of Reclast suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Reclast DMF (Drug Master File) is a document detailing the whole manufacturing process of Reclast active pharmaceutical ingredient (API) in detail. Different forms of Reclast DMFs exist exist since differing nations have different regulations, such as Reclast USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Reclast DMF submitted to regulatory agencies in the US is known as a USDMF. Reclast USDMF includes data on Reclast's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Reclast USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Reclast suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Reclast Drug Master File in Japan (Reclast JDMF) empowers Reclast API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Reclast JDMF during the approval evaluation for pharmaceutical products. At the time of Reclast JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Reclast suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Reclast Drug Master File in Korea (Reclast KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Reclast. The MFDS reviews the Reclast KDMF as part of the drug registration process and uses the information provided in the Reclast KDMF to evaluate the safety and efficacy of the drug.
After submitting a Reclast KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Reclast API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Reclast suppliers with KDMF on PharmaCompass.
A Reclast CEP of the European Pharmacopoeia monograph is often referred to as a Reclast Certificate of Suitability (COS). The purpose of a Reclast CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Reclast EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Reclast to their clients by showing that a Reclast CEP has been issued for it. The manufacturer submits a Reclast CEP (COS) as part of the market authorization procedure, and it takes on the role of a Reclast CEP holder for the record. Additionally, the data presented in the Reclast CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Reclast DMF.
A Reclast CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Reclast CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Reclast suppliers with CEP (COS) on PharmaCompass.
A Reclast written confirmation (Reclast WC) is an official document issued by a regulatory agency to a Reclast manufacturer, verifying that the manufacturing facility of a Reclast active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Reclast APIs or Reclast finished pharmaceutical products to another nation, regulatory agencies frequently require a Reclast WC (written confirmation) as part of the regulatory process.
click here to find a list of Reclast suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Reclast as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Reclast API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Reclast as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Reclast and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Reclast NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Reclast suppliers with NDC on PharmaCompass.
Reclast Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Reclast GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Reclast GMP manufacturer or Reclast GMP API supplier for your needs.
A Reclast CoA (Certificate of Analysis) is a formal document that attests to Reclast's compliance with Reclast specifications and serves as a tool for batch-level quality control.
Reclast CoA mostly includes findings from lab analyses of a specific batch. For each Reclast CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Reclast may be tested according to a variety of international standards, such as European Pharmacopoeia (Reclast EP), Reclast JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Reclast USP).